BB Healthcare

Issue of Equity
RNS Number : 7079T
BB Healthcare Trust PLC
26 March 2021
 

 

26 March 2021

 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT, THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT, THIS DOES NOT INCLUDE THE UK)

 

BB Healthcare Trust plc

 

Issue of Ordinary Shares

 

BB Healthcare Trust plc (the "Company") announces that it has today issued 200,000 of its ordinary shares of one penny each ("Ordinary Shares") pursuant to its block listing facility. The Ordinary Shares will be issued at a price of 186.36 pence per Ordinary Share, a premium to the prevailing net asset value ("cum income") per Ordinary Share.

 

Following the issue of Ordinary Shares, the Company's issued share capital will comprise (515,970,455) Ordinary Shares and this is the total number of Ordinary Shares with voting rights in the Company. This figure (515,970,455) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The Company's LEI is: 213800HQ3J3H9YF2UI82

 

For further information please contact:

 

 Bellevue Asset Management (UK) Ltd.

 Mark Ghahramani

 Telephone: +44 (0) 203 326 2981

 

 J.P. Morgan Cazenove

 James Bouverat (Sales)

 Telephone: +44 (0) 207 134 2224

 

 Alvarium Securities Limited

 Mark Thompson            +44 (0)20 7016 6711

 Eddie Nissen                 +44 (0)20 7016 6713

 Oliver Kenyon                +44 (0)20 7195 1448

 

 

 

 

 

 

Disclaimer

 

This announcement does not constitute a prospectus relating to the Company and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract therefore.

 

 J.P. Morgan Cazenove and Alvarium Securities Limited, which are authorised and regulated by the Financial Conduct Authority, are acting for the Company only in connection with the matters described in this announcement and are not acting for or advising any other person, or treating any other person as their client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of Alvarium Securities Limited and J.P. Morgan Cazenove or advice to any other person in relation to the matters contained herein.

 

The shares of the Company have not been and will not be registered under the US Securities Act of 1933, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Moreover, the shares of the Company have not been, nor will they be, registered under the applicable securities laws of Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom). Further, the Company will not be registered under the US Investment Company Act of 1940, as amended. Subject to certain exceptions, the shares of the Company may not be offered or sold in the United States, Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom or to professional investors in Ireland) or to, or for the account or benefit of, any national, resident or citizen of the United States, Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom or to professional investors in Ireland). The share issuance programme, and the distribution of this announcement, in other jurisdictions may be restricted by law and the persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFLFLDVFIRFIL